It is with great pleasure that I invite you to join 16^th International Breast Cancer Conference & 3^rd  Breast Cancer Survivorship Summit for the 16^th  time in our city. The Conference has established itself as an international conference for breast cancer, and a forum for sharing best clinical practices, inform on the latest scientific updates in the field. This conference is designed to provide state-of-the-art information on the biology, prevention, diagnosis, and therapy of breast cancer to an audience of academic and private physicians and researchers. At the conference all topics will be presented from the perspective of a multi-professional approach. It’s an opportunity to learn from the world leaders in breast cancer. The conference aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with special interest in breast cancer.

In this year we are going to focus on the following:

• Optimal Endocrine Therapy for Breast Cancer – Which Drug and for How Long?
• Risk and Prevention of Anthracycline-Induced Cardiotoxicity Among Breast Cancer Patients
• New Approaches for Decreasing Risk of Lymphedema
• Abbreviated Breast MRI and Contrast Mammography: The New Screening Paradigm?
• Axillary Surgery in The Era of Monarche, Rxponder, Olympia and SOUND Trials
• Management of Loco-Regional Recurrence After Breast Conversation
• Her2-low: How Low Should We Go?
• After NSABP B51: Should Radiotherapy Be Omitted in All Node Positive Patients Who Are Converted to Node N0?
• Integration of Reconstruction and Oncoplastic Surgery with Radiation Therapy: Important Implications for The Surgeons to Know
• Current Therapeutic Strategies for Metastatic Triple Negative Breast Cancer
• Germline Testing in Patients with Breast Cancer
• Which Hormone Receptor Positive Breast Cancer Require Adjuvant Chemotherapy?
• The Role of CDK4/6 Inhibitors in Early and Metastatic HR Positive, Her2 Negative Breast Cancer
• Immunotherapy for High-Risk Early-Stage Breast Cancer: An Overview of Current Strategies and Perspectives
• Current Standards and Future Outlooks in Metastatic Her2 Positive Breast Cancer